Clinical Trial

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-19
Trial Details
NCT Number NCT07242417
Lead Sponsor Beijing GoBroad Hospital
Conditions Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2025-12-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21